Rockwell Medical Inc. (RMTI)
NASDAQ: RMTIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RMTI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $23.12M
- Forward P/E
- 83.14
- EPS (TTM)
- -$1.43
- Dividend yield
- None
- 52-week range
- 4.89 – 12.90
- Day range
- 5.82 – 6.29
- Volume / Avg
- 51.38K / 25.91K
- Beta
- —
- Shares outstanding
- 3.97M
52-week range
RMTI stock today
Shares of Rockwell Medical (RMTI) finished lower on Nov 20 at $5.82, a drop of 7.03% or $0.44 per share, versus the S&P 500's 3.70% decline. At this level, RMTI sits near the bottom of its 52-week range of $4.89 to $12.90: 54.9% below the high, set on Jan 20, 2026 and 19.0% above the low. RMTI is down 29.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.6%.
Rockwell Medical has posted a net loss over the last twelve months (EPS of -$1.43), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Rockwell Medical
Company profileRockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Mark Strobeck Ph.D.
- Headquarters
- Wixom, MI
- Employees
- 157
- IPO year
- 1998
- Website
- rockwellmed.com
Financial highlights
Full financialsIn fiscal 2025, Rockwell Medical generated $69.3 million in revenue, down 31.8% from fiscal 2024, its first annual decline since 2021. Rockwell Medical reported a net loss of $5.3 million, compared with a loss of $480,000 a year earlier. Gross margin was 16.9% (down from 17.2%) and operating margin -6.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $69.26M | $101.49M | $83.61M | $72.81M | $61.93M |
| Growth | -31.76% | +21.38% | +14.84% | +17.57% | -0.43% |
| Net income | $-5.31M | $-480.00K | $-8.44M | $-18.68M | $-32.67M |
| EPS (diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$20.00+243.64%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.59 vs $-0.18
- Surprise
- -227.78%
RMTI news
All RMTI news- Rockwell Medical Reports Third Quarter 2026 Financial Results and Vantive Acquisition AgreementNasdaqRMTI, BF.A
- Rockwell Medical (RMTI) Q3 2026 Earnings Call TranscriptNasdaq
- Rockwell Medical Announces Third Quarter 2026 ResultsBusiness Wire
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%NasdaqNBIX, PTCT, RMTI, SIBN
- Rockwell Medical Announces Transformational Global Hemodialysis AcquisitionBusiness Wire
- Rockwell Medical to Release Third Quarter 2026 Results on Thursday, November 12, 2026Business Wire
- DaVita Stock Benefits From Strengthening Kidney Care DeliveryNasdaqDVA, FMS, RMTI
Rockwell Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMMPImmutep Limited ADR | 3.11 | -9.06% | $22.92M | vs RMTI |
| IXHLIncannex Healthcare Inc. | 1.86 | +6.90% | $23.34M | vs RMTI |
| ABVCABVC BioPharma Inc. | 0.8663 | -1.56% | $23.37M | vs RMTI |
| SCYXSCYNEXIS Inc. | 2.38 | -8.64% | $23.69M | vs RMTI |
| LITSLite Strategy Inc. | 0.8026 | -4.03% | $23.99M | vs RMTI |
| CRVOCervoMed Inc. | 1.46 | +9.77% | $22.09M | vs RMTI |
| AARDAardvark Therapeutics Inc. | 0.9226 | -7.74% | $20.20M | vs RMTI |
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs RMTI |
Indexes, lists and sector
Rockwell Medical stock FAQ
What is Rockwell Medical's stock price today?
RMTI last traded at $5.82 as of Nov 20, 4:00 PM EST, down 7.03% on the day. Prices are delayed at least 15 minutes.
Does Rockwell Medical pay a dividend?
No. Rockwell Medical does not currently pay a regular cash dividend.
Who is Rockwell Medical's CEO?
Dr. Mark Strobeck Ph.D. is the chief executive officer of Rockwell Medical Inc., which has about 157 employees.
Has RMTI ever split its stock?
Yes. The most recent RMTI stock split was a 1-for-10 split on Jul 1, 2026, one of 2 splits on record.
What is the RMTI 52-week high?
The 52-week high for RMTI is $12.90 and the 52-week low is $4.89. The stock is currently 54.9% below its high.